Skip to main content
< Back to news
David Bermúdez (Photo: Parc Científic de Barcelona, Daniel Portales).

David Bermúdez, new CEO of Intelligent Pharma

Engineer, David Bermúdez, until now Director of Technology at Intelligent Pharma, has been appointed CEO of this biotech located at the Barcelona Science Park (PCB). Bermúdez takes on this new challenge as of the 1st September and brings nearly twenty years of professional experience in research, development and leadership of innovative interdisciplinary projects in the field of ICT, artificial intelligence, supercomputing and drug design.


David Bermúdez García (Hospitalet de Llobregat, 1979) is a computer engineer (Polytechnic University of Catalonia) and graduate in Business Administration and Management from the Open University of Catalonia (UOC). He has also completed the executive program on Innovation Management by the EOI Business School. He complimented his training with various postgraduate courses in artificial intelligence, data analysis, and computational statistics from the Stanford University (California, USA) and the Johns Hopkins University (Maryland, USA).

His professional career has been linked to research, development and innovation in the field of information and communications technology (ICT), software engineering and supercomputing in major industrial and service companies. In 2011, he joined the Department of  R&D at Intelligent Pharma where he has held the position of Chief Technical Officer (CTO) since 2014, leading the development of innovative technologies applied to computational chemistry (molecular engineering) for clients worldwide within the pharmaceutical, biotechnology, cosmetics, and most recently petrochemical companies, among others.

Bermúdez –who replaces Ignasi Belda, founder and chairman of Intelligent Pharma since it was first created in 2007- has as primary objectives as head of the company “to continue the model and business lines established by the previous management, which allowed us to be an international company providing services in computational chemistry for drug discovery; maintaining our technological leadership, promoting the generation of R&D; increasing commercial investment to preserve our competitiveness in the internal and external markets. Other top priorities include continued expansion in other countries and the consolidation of new collective agreements and partnerships with public institutions and companies in the industry.”